Journal ArticleDOI
Treatment of metastasising grf-producing tumour with a long-acting somatostatin analogue
KlausVon Werder,M. Losa,O. Albrecht Müller,Leonhard Schweiberer,Rudolf Fahlbusch,EmilioDel Pozo +5 more
About:
This article is published in The Lancet.The article was published on 1984-08-04. It has received 63 citations till now.read more
Citations
More filters
Journal ArticleDOI
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
John Ramage,A Ahmed,J Ardill,N.D.S. Bax,David J. Breen,Martyn Caplin,Pippa Corrie,J Davar,Albert Davies,Val Lewington,Tim Meyer,John Newell-Price,Graeme J. Poston,N. Reed,Andrea Rockall,William P. Steward,Rajesh V. Thakker,C. Toubanakis,Juan W. Valle,Caroline S. Verbeke,Ashley B. Grossman +20 more
TL;DR: These guidelines update previous guidance published in 2005 and have been revised by a group who are members of the UK and Ireland Neuroendocrine Tumour Society with endorsement from the clinical committees of the British Society of Gastroenterology and others.
Journal ArticleDOI
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system
Kjell Öberg,Larry K. Kvols,Martyn Caplin,G. Dell Fave,W. W. de Herder,Guido Rindi,Philippe Ruszniewski,Eugene A. Woltering,Bertram Wiedenmann +8 more
TL;DR: This consensus report gives a detailed description of the use of somatostatin analogs in the management of neuroendocrine tumors of the gastroenteropancreatic system and defines the binding affinities of different somatosteroid analogs to the five different subtypes of som atostatin receptor.
Journal Article
Somatostatin Receptors in Human Endocrine Tumors
Jean Claude Reubi,R. Maurer,K. von Werder,Joachim Torhorst,Jan G. M. Klijn,S. W. J. Lamberts +5 more
TL;DR: The present data could be of potential therapeutic interest if they can mediate antiproliferative properties, as has been suggested to be the case for somatostatin receptors in selected endocrine tumors in rats and humans.
Journal ArticleDOI
Somatostatin and Somatostatin Analogue (SMS 201-995) in Treatment of Hormone-Secreting Tumors of the Pituitary and Gastrointestinal Tract and Non-Neoplastic Diseases of the Gut
TL;DR: In patients with the carcinoid syndrome, SMS 201-995 effectively reduces diarrhea, is the best available drug for treatment of carcinoid flush, and is useful in treating carcinoid crisis, and whether the long-term use of the drug will result in an iatrogenic form of the somatostatinoma syndrome is uncertain.
Journal ArticleDOI
Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin.
J. Pless,W. Bauer,U. Briner,W. Doepfner,P. Marbach,R Maurer,T. J. Petcher,J.-C. Reubi,J Vonderscher +8 more
TL;DR: The stability and duration of action of SMS 201-995 after subcutaneous injection enable for the first time extended investigations of the clinical utility of somatostatin in various diseases.
References
More filters
Journal ArticleDOI
SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.
TL;DR: The analogue H-(D) Phe-Cys-Phe-( D) Trp-Lys-Thr-CYS-ThR(ol) code-named SMS 201-995, which in vitro is three times more potent than the native hormone in inhibiting the secretion of growth hormone, is well tolerated both in laboratory animals and in man.
Journal ArticleDOI
Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly.
Roger Guillemin,Paul Brazeau,Peter Bohlen,Frederick Esch,Nicholas Ling,William B. Wehrenberg +5 more
TL;DR: A 44 amino acid peptide with growth hormone-releasing activity has been isolated from a human tumor of the pancreas that had caused acromegaly and has full biological activity in vitro and in vivo specifically to stimulate the secretion of immunoreactive growth hormone.
Journal ArticleDOI
Somatotroph Hyperplasia: SUCCESSFUL TREATMENT OF ACROMEGALY BY REMOVAL OF A PANCREATIC ISLET TUMOR SECRETING A GROWTH HORMONE-RELEASING FACTOR
Michael O. Thorner,Richard L. Perryman,Michael J. Cronin,Alan D. Rogol,Martin B. Draznin,Ann J. Johanson,Wylie Vale,Eva Horvath,Kalman Kovacs +8 more
TL;DR: Elevated serum GH and somatomedin C levels in a patient with an enlarged sella turcica and the characteristic responses seen in acromegaly to TRH, dopamine, and glucose do not occur exclusively in patients with discrete pituitary tumors and acromegalic, so consideration of ectopic GRF secretion should be made.
Journal Article
Somatotroph hyperplasia: successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor.
Michael O. Thorner,Richard L. Perryman,Michael J. Cronin,Martin B. Draznin,Ann J. Johanson,Alan D. Rogol,John A. Jane,Rudolf Le,Eva Horvath,Kalman Kovacs,Wylie Vale +10 more